AliveDx Suisse S.A. and Kyungil Hi-tec INC have signed an exclusive distribution agreement, which will enable Kyungil Hi-tec to distribute the MosaiQ® solution in South Korea. The distribution agreement takes effect immediately.
This strategic partnership with an important partner in South Korea reaffirms AliveDx’s commitment to expanding its geographical presence and creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis. It will enable both parties to introduce new quality services to the healthcare industry and enhance patient care in the country.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“We are proud to announce our partnership with another key player in the APAC market. We are eager to join forces with Kyungil Hi-tec and to make a strategic impact on improving patients’ lives throughout the region,” said Manuel O. Méndez, AliveDx’s CEO.
Kyungil Hi-tec has over 35 years of experience in the In Vitro Diagnostics (IVD) field in South Korea. With a deep understanding of the South Korean medical distribution landscape and keen insights from patients and healthcare professionals, Kyungil Hi-tec is committed to investing in customer training, education, and clinical evaluation support, as well as ensuring high standards of product quality and services.
“We are honored to collaborate with AliveDx. Adding the MosaiQ solution to our portfolio signifies our continued expansion into the immunology diagnostics segment. We believe this partnership will enable us to bring South Korea’s healthcare sector the latest, best-in-class technologies, positively impacting patients’ lives,” said President Lee, Founder & CEO of Kyungil Hi-tec.
